Katairo GmbH is a biopharmaceutical company developing novel drugs for the treatment of eye diseases. In the leading program pioneering properties of the substance Remofuscin are investigated. Remofuscin is able to break down and remove from the cells of the retina the harmful waste product of eye metabolism - Lipofuscin. With this entirely novel effect Remofuscin provides a treatment of lipofuscin associated retinal degenerative diseases such as Stargardt's disease or age-related macular degeneration.
Katairo 2011 was spun off from the University of Tübingen, where Prof. Dr. Schraermeyer made fundamental discoveries, for which he was awarded in 2012 the Innovation Award of bioregions in Germany.
In November 2013 Katairo received the Orphan Medicinal Product Designation from the European Commission for the treatment of Stargardt disease with Remofuscin.
|Year of foundation|
Finanziert durch Investment der Gründer
P +49-7071-549 6182
F +49-7071-549 6183
info [at] katairo.com
Dr. Wolfgang Klein, CEO